CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
305.46
0.32%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.55
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023624 %
Charges from full value of position ($-4.49)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023624%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001401 %
Charges from full value of position ($0.27)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001401%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 306.44
Open 302.74
1-Year Change 6.98%
Day's Range 300.97 - 306.12
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 1, 2025 306.44 -3.77 -1.22% 310.21 312.30 304.88
Mar 31, 2025 311.19 3.78 1.23% 307.41 314.65 305.37
Mar 28, 2025 306.86 -0.37 -0.12% 307.23 308.02 304.28
Mar 27, 2025 304.90 -0.35 -0.11% 305.25 307.42 303.45
Mar 26, 2025 305.56 -1.25 -0.41% 306.81 308.83 303.57
Mar 25, 2025 306.43 -6.38 -2.04% 312.81 313.44 303.07
Mar 24, 2025 314.02 -0.33 -0.10% 314.35 317.39 313.21
Mar 21, 2025 315.24 3.54 1.14% 311.70 316.02 309.87
Mar 20, 2025 314.89 2.09 0.67% 312.80 315.26 311.94
Mar 19, 2025 315.67 -0.07 -0.02% 315.74 318.39 313.21
Mar 18, 2025 317.90 0.66 0.21% 317.24 319.20 314.08
Mar 17, 2025 316.91 3.88 1.24% 313.03 318.30 310.96
Mar 14, 2025 312.81 0.91 0.29% 311.90 314.28 309.72
Mar 13, 2025 312.59 2.49 0.80% 310.10 316.40 310.10
Mar 12, 2025 312.24 1.05 0.34% 311.19 315.58 308.39
Mar 11, 2025 318.58 -9.92 -3.02% 328.50 328.75 318.04
Mar 10, 2025 327.16 4.21 1.30% 322.95 335.65 322.95
Mar 7, 2025 324.78 6.81 2.14% 317.97 328.04 317.48
Mar 6, 2025 317.75 1.97 0.62% 315.78 318.25 312.40
Mar 5, 2025 315.78 4.90 1.58% 310.88 318.79 308.74

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Amgen Company profile

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).

Equity composition

Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).

Industry: Pharmaceuticals (NEC)

One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US

People also watch

US100

18,687.30 Price
-3.680% 1D Chg, %
Long position overnight fee -0.0236%
Short position overnight fee 0.0014%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,795.78 Price
-6.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

XRP/USD

2.04 Price
-5.460% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01016

BTC/USD

82,527.25 Price
-3.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 710,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading